Stay updated with breaking news from Per Hellsund. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
– CBX-12 has potential to improve efficacy and reduce toxicity over systemic topoisomerase inhibitors –– Deal reflects Exelixis’ strategic focus on expanding its clinical pipeline and building upon its growing biotherapeutics expertise –ALAMEDA, Calif. & NEW HAVEN, Conn.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXE...
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Investegate announcements from Cybrexa Therapeutics, Cybrexa Therapeutics Announces Data Demonstrating Early Signals of Efficacy and Powerful Potential of Antigen-Independent Tumor Targeting
(0) - Study to determine safety and tolerability of CBX-12 and establish recommended Phase 2 dose - NEW HAVEN, Conn., May 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the first patient has been dosed in a Phase 1/2 clinical trial evaluating CBX-12 (alphalex-exatecan), the company's lead therapeutic candidate. The open-label, multicenter study will evaluate CBX-12 in patients with advanced or metastatic refractory sol...
Cybrexa Therapeutics Closes $25 Million Series B Financing -Proceeds will advance the company's lead program into clinical trials- NEW HAVEN, Conn., March 10, 2021 (GLOBE NEWSWIRE) -- Cybrexa Therapeutics, an oncology-focused biotechnology company developing a new class of therapeutics through its alphalex Peptide Drug Conjugate (PDC) tumor targeting platform, today announced the completion of its $25 million Series B financing. The financing included HighCape Capital and new investor Elm Street Ventures. Proceeds from the financing will be used to support the planned advancement of Cybrexa...